MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

A breast cancer patient self funding her treatment has said it's unfair she has to pay GST on the drugs that are already costing her ten of thousands of dollars. Wellington woman Amanda Broughton has ...

Wellington woman Amanda Broughton will have to pay $103,000 for a course of a drug, to treat her stage 3C breast cancer. The ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Lantern Pharma (NASDAQ: LTRN) announced a remarkable clinical outcome in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker with advanc ...

The recent experience of Chinese biotech companies in developing their own drug candidates and inking deals with larger ...

DelveInsight’s Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ ...

Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.